Business
ABIONYX Pharma Carries Out a Capital Increase With Cancellation of Preferential Subscription Rights in Favor of Certain Categories of Persons, Amounting to Approximately €1.8m
TOULOUSE, France & FULLERTON, Calif., December 17, 2025--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today carries out a capital increase with the removal of preferential subscription rights ("PSR") for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new sh
About this update from Abionyx Pharma Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Capital increase of approximately 1.8 million euros","length":51,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Subscription price: 3.10 euros","length":30,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Extension of financial visibility until the end of 2026","length":55,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":136,"olType":false},{"type":"text","content":"TOULOUSE, France & FULLERTON, Calif., December 17, 2025--(BUSINESS WIRE)--Regulatory News:","length":94,"tagName":"p"},{"type":"text","content":"ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its proprietary apoA-I–based technology platform, today carries out a capital increase with the removal of preferential subscription rights ("PSR") for certain categories of persons, for an amount of nearly 1.8 million euros through the issuance of 580,643 new shares at a subscription price of 3.10 euros (the "Issuance").","length":506,"tagName":"p"},{"type":"text","content":"Terms and conditions of the Issue","length":33,"tagName":"p"},{"type":"text","content":"Following the Issuance decision taken on December 16, 2025, the Chief Executive Officer today confirmed the full subscription of 580,643 new shares at a price of €3.10 per share (representing a 10% discount on the closing price on December 16, 2025). This issue represents approximately 1.66% of the share capital on the date of the Issue decision.","length":348,"tagName":"p"},{"type":"text","content":"This transaction is part of a capital increase with the removal of preferential subscription rights in favor of persons belonging to specific categories, decided by the Board of Directors on December 16, 2025, acting on the basis of the delegation granted by the General Meeting of June 26, 2025, under its fourteenth extraordinary resolution.","length":343,"tagName":"p"},{"type":"text","content":"The total amount of the capital increase is €1,799,993.30 (including €29,032.15 in nominal value and a share premium of €1,770,961.15). The new shares will carry current dividend rights, will be treated as existing shares and will enjoy the same rights. They will be subject to all statutory provisions and wi...